CLSD - Clearside Biomedical, Inc.
IEX Last Trade
0.9558
0.006 0.607%
Share volume: 3,262
Last Updated: Fri 27 Dec 2024 08:30:04 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$0.95
0.01
0.61%
Fundamental analysis
38%
Profitability
25%
Dept financing
48%
Liquidity
75%
Performance
40%
Performance
5 Days
5.72%
1 Month
-13.08%
3 Months
-19.83%
6 Months
-27.34%
1 Year
-21.19%
2 Year
-16.22%
Key data
Stock price
$0.96
DAY RANGE
$0.94 - $0.96
52 WEEK RANGE
$0.92 - $2.12
52 WEEK CHANGE
-$20.51
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: George M. Lasezkay
Region: US
Website: clearsidebio.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: clearsidebio.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Clearside Biomedical, Inc. focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprchoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX and CLS-301, an integrin inhibitor suspension for macular degeneration.
Recent news